Phase 1 Pancreatic cancer trials recruiting now

All Pancreatic cancer trials, every phase

Other phases for Pancreatic cancer

Phase 1 Pancreatic cancer trials

• 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
  NCT06298916 · Phase: Phase 1, Phase 2 · Ages: 15 Years and older · Sex: All (male and female) · 10 locations
• A 2-part Phase 1/2 Open-label Trial on ODM-212
  NCT07563738 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
  NCT06760364 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  NCT06428409 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
  NCT06043466 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
  NCT07049055 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
  NCT07186842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
  NCT07481357 · Phase: Phase 1 · Ages: 19 Years and older · Sex: All (male and female) · 3 locations
• A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
  NCT07481383 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
  NCT07458347 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
  NCT07157033 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
  NCT06533332 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
  NCT06898385 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
  NCT06508307 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
  NCT06403735 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
  NCT06883539 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
  NCT06245330 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
  NCT06380816 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
  NCT06959615 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 64 locations
• A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
  NCT07040228 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
  NCT06758544 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
  NCT07024615 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
  NCT05365581 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 46 locations
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
  NCT05262491 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
  NCT06500052 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of DEG6498 in Participants With Solid Tumors
  NCT07244835 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of DM002 in Patients With Advanced Solid Tumors
  NCT06751329 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
  NCT07671339 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  NCT06983743 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 24 locations
• A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
  NCT06782555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
  NCT07172802 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors
  NCT07106827 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
  NCT05740956 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
  NCT07277413 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study of JMT203 in Patients With Cancer Cachexia
  NCT06868849 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
  NCT07229313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
  NCT06400472 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
  NCT07213791 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MGC028 in Participants With Advanced Solid Tumors
  NCT06723236 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
  NCT07066657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
  NCT07701486 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
  NCT05403554 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
  NCT06907043 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 10 locations
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• A Study of PHN-012 in Patients With Advanced Solid Tumors
  NCT07127874 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 78 locations
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
  NCT06914128 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 63 locations
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
  NCT07300150 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
  NCT07705334 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 158 locations
• A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
  NCT06385925 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 57 locations
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
  NCT05706129 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 40 locations
• A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
  NCT06598007 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
  NCT06179160 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
  NCT05941507 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
  NCT05911217 · Phase: Phase 1 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 120 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
  NCT07094204 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
  NCT07090499 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
  NCT06885034 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 170 locations
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
  NCT04503265 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
  NCT04678648 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
  NCT07619313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
  NCT07094113 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
  NCT07444541 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• AOH1996 for the Treatment of Refractory Solid Tumors
  NCT05227326 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
  NCT07454642 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
  NCT06844422 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adenovirus (RGDCRAdCOX2F)
  NCT06693986 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
  NCT03190941 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
  NCT07360314 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
  NCT06885697 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Autologous CAR-T Cells Targeting B7-H3 in PDAC
  NCT06158139 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
  NCT07594626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
  NCT06483555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
  NCT03740256 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
  NCT07523529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations

Showing 100 of 257 recruiting trials.

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.